Trials / Recruiting
RecruitingNCT07356154
A Study of Revumenib and Mezigdomide in People With Leukemia
A Phase 1/2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed/Refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
Conditions
- Leukemia
- Acute Leukemia
- Relapse Leukemia
- Refractory Leukemia
- Refractory Acute Leukemia
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Mixed Phenotype Acute Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Revumenib | Revumenib is a novel menin inhibitor |
| DRUG | Mezigdomide | Mezigdomide (CC-92480) is an investigational CELMoD. |
Timeline
- Start date
- 2026-01-16
- Primary completion
- 2029-01-16
- Completion
- 2029-01-16
- First posted
- 2026-01-21
- Last updated
- 2026-01-21
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07356154. Inclusion in this directory is not an endorsement.